Studies on The Potential Cancer-Targeting and Biomarker Properties of C1orf52

Target Name: C1orf52

NCBI ID: G148423

C1orf52

Studies on The Potential Cancer-Targeting and Biomarker Properties of C1orf52

C1orf52 (RP11-234D19.1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation, which results in the substitution of a single nucleotide for a thymine base, has been shown to cause a range of molecular and cellular changes that can be linked to disease.

The C1orf52 gene is located on chromosome 11 and encodes a protein known as CRTBP, which is a key regulator of microRNA (miRNA) levels in the cell. MiRNA are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation by binding to specific target genes and regulating their expression levels.

In addition to its role in miRNA regulation, C1orf52 has also been shown to be involved in a number of other cellular processes that are important for human health and disease. For example, it has been shown to be involved in cell adhesion, migration, and the development of cancer.

The substitution of a single nucleotide for a thymine base in the C1orf52 gene has been shown to result in a range of cellular and molecular changes. This includes changes to the expression of other genes, such as the TCF7L gene, which is involved in cell adhesion and migration. The substitution of thymine for guanine has also been shown to result in the activation of a number of cellular pathways that are associated with disease, including the JAK/STAT signaling pathway, which is involved in the regulation of inflammation and immune responses.

In addition to its role in disease, the C1orf52 gene has also been shown to have potential as a drug target or biomarker. Studies have shown that inhibiting the activity of C1orf52 has the potential to treat a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, experiments have shown that inhibiting the activity of C1orf52 has the potential to enhance the efficacy of chemotherapy in cancer treatment, as it has been shown to inhibit the development of cancer cell resistance to chemotherapy.

In addition to its potential as a drug target or biomarker, the C1orf52 gene also has important implications for our understanding of human disease. The substitution of a single nucleotide for a thymine base has been shown to result in a range of cellular and molecular changes that can be linked to disease. These changes may be important for the development and progression of disease, and may also play a role in the regulation of normal cellular processes.

Overall, the C1orf52 gene is a promising target for drug development and research into the mechanisms of disease. Further studies are needed to fully understand its role in human disease and to develop effective treatments.

Protein Name: Chromosome 1 Open Reading Frame 52

The "C1orf52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets